In-vivo 31P MRSI in healthy and malignant human pancreas at 7 Tesla
Leonard W.F. Seelen1,2, Lieke van den Wildenberg1, Ayhan Gursan1, Tijl A. van der Velden1, Mark Gosselink1, Martijn Froeling1, Wybe J.M. van der Kemp1, Firdaus A.A. Mohamed Hoesein3, Nadia Haj Mohammad4, I. Quintus Molenaar2, Hjalmar C. van Santvoort2, Dennis W.J. Klomp1, and Jeanine J. Prompers1
1Dept. of Radiology, University Medical Center Utrecht, Utrecht, Netherlands, 2Dept. of Surgery, UMC Utrecht Cancer Center and St Antonius Hospital Nieuwegein: Regional Academic Cancer Center Utrecht, Utrecht University, Utrecht, Netherlands, 3Dept. of Radiology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands, 4Dept. of Medical Oncology, UMC Utrecht Cancer Center, Regional Academic Cancer Center Utrecht, Utrecht University, Utrecht, Netherlands
Early response assessment for patients with pancreatic cancer receiving chemotherapy is limited. Detection of alterations in 31P metabolite levels during treatment could change this perspective. However, to date 31P MRS has not yet been demonstrated in the human pancreas in vivo. Here we show in-vivo 31P MRSI data in the pancreas of healthy subjects, using a 31P whole-body transmit coil in combination with a 16-channel receive array at 7T, and show moderate to good test-retest reliability. In addition, we demonstrate the feasibility of performing 31P MRSI in a patient with pancreatic cancer before and after chemotherapy.
This abstract and the presentation materials are available to members only;
a login is required.